When was Exagen founded?

Exagen was founded in 2002 and raised its 1st funding round 2 years after it was founded.

Where is Exagen located?

Exagen is headquartered in Vista, United States.

How many employees does Exagen have?

As of Jun 30, 2026, the latest employee count at Exagen is 215.

Is Exagen a funded company?

Exagen is a funded company, having raised a total of $110M across 36 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jan 01, 2004.

When was the latest funding round of Exagen?

Exagen's latest funding was a $***** Series C round on Jul 16, 2019, with participation from 1 investor.

What is the annual revenue of Exagen?

Annual revenue of Exagen is between $50M and $100M as on Dec 31, 2025

Where does Exagen rank among its competitors?

Exagen ranks 1st amongst 89 active competitors, of which 16 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Daye, which secured $576K in Nov, 2025.

Who are the top competitors of Exagen?

Exagen's top competitors include Daye, Proxim Diagnostics and Oncimmune. Among them, Daye secured the most recent funding round in November, 2025.

Exagen - 2026 Company Profile, Funding, Competitors & Financials

Exagen is a public company based in Vista (United States), founded in 2002. It operates as a Developer of diagnosis, prognosis and monitoring solutions for autoimmune connective diseases. Exagen has raised $110M in funding from Tullis Health Investors and HIG BioHealth Partners. The company has 89 active competitors, including 16 funded and 13 that have exited. Its top competitors include companies like Daye, Proxim Diagnostics and Oncimmune.

Company Details

Developer of diagnosis, prognosis, and monitoring solutions for autoimmune connective diseases. The products include Avise CTD is an autoimmune Connective Tissue Disease (CTD) diagnostic that helps physicians in the differential diagnosis of RA, Lupus, Fibromyalgia, Sjogren's, Scleroderma, PM/DM, APS, and Autoimmune Thyroid disease by using CB-CAPs (Cell-Bound Complement Activation Products) technology. Avise SLE Prognostic is a 10-biomarker panel to help assess a patient’s potential risk for Thrombosis, Cardiovascular events, Lupus Nephritis, and Neuropsychiatric Lupus. Avise Adalimumab and Avise Infliximab enable physicians to monitor drug level activity and neutralize anti-drug antibodies, thus optimizing patient treatment. Avise MTX measures active methotrexate (MTXPGs) to help physicians assess their patients' MTX dose; exposure. Avise HCQ is a drug monitoring test that provides a measurement of HCQ (Hydroxychloroquine) levels in whole blood to help physicians assess their patients' compliance and exposure to HCQ therapy. Avise Lupus is a diagnostic tool that helps physicians detect difficult-to-diagnose lupus.

Key Metrics

Founded Year

2002

Location

Vista, United States

Stage

Public

Total Funding

$110M in 36 rounds

Latest Funding Round

Series C, Jul 16, 2019, $*****

Investors

Tullis Health Investors & 11 more

Ranked

1^st among 89 active competitors

Annual Revenue

$50M - $100M as on Dec 31, 2025

Employee Count

215 as on Jun 30, 2026

Similar Companies

Proxim Diagnostics & 71 more

Exit Details

Public

View Exagen's full profile

Exagen is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Exagen Inc. CIN: 1274737 , United States, Active	Nov 16, 2003	$50M - $100M (As on Dec 31, 2025)	204 (As on Dec 31, 2022)	-
Exagen Inc. CIN: 20-0434866 , United States, Active	Nov 16, 2003	-	219 (As on Dec 31, 2021)	-
EXAGEN DIAGNOSTICS INC CIN: 1274737 , United States, Active		$5M - $25M (As on Oct 14, 2013)	-	-

Exagen got listed on Sep 19, 2019.

Click here to take a look at Exagen's IPO in detail

Exagen has raised a total funding of $110M over 36 rounds. Its first funding round was on Jan 01, 2004. Its latest funding round was a Series C round on Jul 16, 2019 for $*****. 1 investor participated in its latest round. Exagen has 12 institutional investors.

Here is the list of recent funding rounds of Exagen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 16, 2019	7097942	Series C	1042010	7246268	8167868	1611003
Feb 01, 2019	8617340	Series C	5066631	8389258	8289512	7560216
Sep 11, 2017	9980928	Conventional Debt	6062901	7352641	6226184	Innovatus Capital Partners

Access funding benchmarks and valuations. Sign up today!

View details of Exagen's funding rounds and investors

Exagen's employee count trend

Exagen has 215 employees as of Jun 26. Here is Exagen's employee count trend over the years:

Uncover Exagen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Exagen include Daye, Proxim Diagnostics and Oncimmune. Here is the list of Top 10 competitors of Exagen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Exagen 2002, Vista (United States), Public	Developer of diagnosis, prognosis and monitoring solutions for autoimmune connective diseases	$110M	EPIC Ventures, Innovatus Capital Partners ... & 10 others	65/100
2nd	Daye 2018, London (United Kingdom), Series A	Manufacturer of period care products and provider of health tests	$19.2M	Salica Investments, Khosla Ventures & 24 others	60/100
3rd	Proxim Diagnostics 2010, Sunnyvale (United States), Series B	Developer of a handheld immunodiagnostic device for cardiac vascular diseases	$22.9M	BioMerieux, UCLA Ventures & 1 others	58/100
4th	Oncimmune 2006, Cambridge (United States), Acquired	Immunodiagnostics company developing biomarker platforms for cancer and immune diseases	-	IPF Partners, Balderton Capital & 9 others	58/100
5th	SmartHealth 1979, Irvine (United States), Series B	Developer precision diagnostics for vascular, metabolic, and oncological diseases	$17.3M	-	49/100
6th	HYCOR BioMedical 1981, Garden Grove (United States), Series D	Developer of diagnostic instruments and reagents for autoimmune diseases and allergies	$99.6M	Linden Capital Partners, GPB Capital	49/100
7th	Virax Biolabs 2013, London (United Kingdom), Public	Developer and distributor of diagnostic test kits	-	-	43/100
8th	Kypha 2009, Dublin (Ireland), Series A	in-vitro diagnostic biomarker tests for inflammation and autoimmune disease	$16.8M	Billiken Angels Network, BioGenerator & 7 others	43/100
9th	Beikang Medical 2010, Suzhou (China), Public	Developer of NGS-based diagnostic solutions for neonatal	$36.5M	Broad Vision Funds, Yixiang Capital & 3 others	43/100
10th	Cell IDx 2012, San Diego (United States), Acquired	Advancing cancer diagnostics and improving lives through innovative solutions	$1.34M	-	41/100